arilocacabtagene autoleucel

Arilocacabtagene autoleucel (BMS-986393; CC-95266) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). Developed by Bristol Myers Squibb, this cell therapy is engineered to recognize and eliminate malignant plasma cells that overexpress GPRC5D, a protein with high specificity for multiple myeloma cells compared to normal tissues. The manufacturing process utilizes a next-generation platform designed to enhance T-cell potency and persistence. Arilocacabtagene autoleucel is primarily being investigated for the treatment of relapsed or refractory multiple myeloma, including in patients who have previously received BCMA-directed therapies, where it has demonstrated significant clinical activity in early-phase trials.

Other names

ariloca-celGPRC5D-targeted CAR T-cell therapyGPRC-5D-targeted CAR T-cell therapyGPRC 5D-targeted CAR T-cell therapy